Idbaih, Ahmed <br/><br/>
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.  [electronic resource] 

 -  Journal of neuro-oncology  Jun 2011 
 - 221-30 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7373 
<br/><br/><label>Standard No.: </label>10.1007/s11060-010-0380-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols<br/>Biomarkers, Tumor--analysis<br/>Brain Neoplasms--drug therapy<br/>Chromosome Aberrations<br/>Chromosomes, Artificial, Bacterial<br/>Combined Modality Therapy<br/>Comparative Genomic Hybridization<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Kaplan-Meier Estimate<br/>Lomustine--administration & dosage<br/>Male<br/>Middle Aged<br/>Multicenter Studies as Topic<br/>Oligodendroglioma--drug therapy<br/>Procarbazine--administration & dosage<br/>Prognosis<br/>Proportional Hazards Models<br/>Radiotherapy<br/>Retrospective Studies<br/>Treatment Outcome<br/>Vincristine--administration & dosage<br/>Young Adult